Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
Menarini Group announced today that it will present the results of two different preclinical studies on MEN1611 at the upcoming 2020 San Antonio Breast Cancer Symposium, which will be held virtually on December 8-11.
SEL24/MEN1703 is being Evaluated for the Treatment of Acute Myeloid Leukemia (AML) Poster Accepted for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Menarini Ricerche, the R&D division of the Menarini Group, announced today that it has treated the first patient in Europe for the cohort expansion part of DIAMOND-01 clinical trial
Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last